Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (101-110 of 255) with videos related to

Pageof 26
Sort By:
Journal of Cancer Survivorship : Research and Practice|April 22, 2015
A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trialAnnelies H Boekhout, Elizabeth Maunsell, Gregory R Pond, et al.
European Urology|October 27, 2015
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysisPatrizia Giannatempo, Gregory R Pond, Guru Sonpavde, et al.
BJU International|October 5, 2016
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapyGuru Sonpavde, Gregory R Pond, Stephanie Mullane, et al.
Cancers|December 30, 2025
The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024)Rebecca Y Xu, Diana Kato, Victoria Percival, et al.
Journal of Bone Oncology|December 9, 2020
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician surveyMashari AlZahrani, Mark Clemons, Lisa Vandermeer, et al.
Blood Cancer Journal|October 16, 2024
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort studyGhulam Rehman Mohyuddin, Hira Mian, Anastasia Gayowsky, et al.
Journal of Geriatric Oncology|July 19, 2025
Longitudinal changes in cognition in older individuals receiving lymphoma-directed therapy: A pilot feasibility studyAmaris K Balitsky, Gregory R Pond, Hira Mian, et al.
Journal of the American Medical Informatics Association : JAMIA|January 2, 2003
Speech recognition as a transcription aid: a randomized comparison with standard transcriptionDavid N Mohr, David W Turner, Gregory R Pond, et al.
Cancer|March 3, 2026
Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximabGwynivere A Davies, Anca Prica, Zharmaine Ante, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Pageof 26

Showing results (101-110 of 255) with videos related to

Sort By:
Pageof 26
Journal of Cancer Survivorship : Research and Practice|April 22, 2015
A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trialAnnelies H Boekhout, Elizabeth Maunsell, Gregory R Pond, et al.
European Urology|October 27, 2015
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysisPatrizia Giannatempo, Gregory R Pond, Guru Sonpavde, et al.
BJU International|October 5, 2016
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapyGuru Sonpavde, Gregory R Pond, Stephanie Mullane, et al.
Cancers|December 30, 2025
The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024)Rebecca Y Xu, Diana Kato, Victoria Percival, et al.
Journal of Bone Oncology|December 9, 2020
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician surveyMashari AlZahrani, Mark Clemons, Lisa Vandermeer, et al.
Blood Cancer Journal|October 16, 2024
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort studyGhulam Rehman Mohyuddin, Hira Mian, Anastasia Gayowsky, et al.
Journal of Geriatric Oncology|July 19, 2025
Longitudinal changes in cognition in older individuals receiving lymphoma-directed therapy: A pilot feasibility studyAmaris K Balitsky, Gregory R Pond, Hira Mian, et al.
Journal of the American Medical Informatics Association : JAMIA|January 2, 2003
Speech recognition as a transcription aid: a randomized comparison with standard transcriptionDavid N Mohr, David W Turner, Gregory R Pond, et al.
Cancer|March 3, 2026
Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximabGwynivere A Davies, Anca Prica, Zharmaine Ante, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Pageof 26